Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Menlo Therapeutics stock

Own Menlo Therapeutics stock in just a few minutes.

Menlo Therapeutics Inc is a biotechnology business based in the US. Menlo Therapeutics shares (MNLO) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Menlo Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MNLO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Menlo Therapeutics share price

Use our graph to track the performance of MNLO stocks over time.

Menlo Therapeutics shares at a glance

Information last updated 2021-03-07.
52-week range$1.00 - $3.60
50-day moving average $1.78
200-day moving average $1.70
Wall St. target price$8.56
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.82

Buy Menlo Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Menlo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Menlo Therapeutics financials

Revenue TTM $13.6 million
Gross profit TTM $443,000
Return on assets TTM -68.11%
Return on equity TTM 0%
Profit margin 0%
Book value $0.43
Market capitalisation $82.5 million

TTM: trailing 12 months

Shorting Menlo Therapeutics shares

There are currently 11.2 million Menlo Therapeutics shares held short by investors – that's known as Menlo Therapeutics's "short interest". This figure is 62% up from 6.9 million last month.

There are a few different ways that this level of interest in shorting Menlo Therapeutics shares can be evaluated.

Menlo Therapeutics's "short interest ratio" (SIR)

Menlo Therapeutics's "short interest ratio" (SIR) is the quantity of Menlo Therapeutics shares currently shorted divided by the average quantity of Menlo Therapeutics shares traded daily (recently around 2.4 million). Menlo Therapeutics's SIR currently stands at 4.59. In other words for every 100,000 Menlo Therapeutics shares traded daily on the market, roughly 4590 shares are currently held short.

However Menlo Therapeutics's short interest can also be evaluated against the total number of Menlo Therapeutics shares, or, against the total number of tradable Menlo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Menlo Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Menlo Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0697% of the tradable shares (for every 100,000 tradable Menlo Therapeutics shares, roughly 70 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Menlo Therapeutics.

Find out more about how you can short Menlo Therapeutics stock.

Menlo Therapeutics share dividends

We're not expecting Menlo Therapeutics to pay a dividend over the next 12 months.

Menlo Therapeutics share price volatility

Over the last 12 months, Menlo Therapeutics's shares have ranged in value from as little as $1 up to $3.6. A popular way to gauge a stock's volatility is its "beta".

MNLO.US volatility(beta: 1.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Menlo Therapeutics's is 1.6857. This would suggest that Menlo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Menlo Therapeutics overview

Menlo Therapeutics Inc. , a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site